SCHEMBL12136331

SCHEMBL12136331

COCCCc1cccc(C)c1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.55
ALDH1A1 P00352 1/20 0.49
CYP2D6 P10635 1/20 0.49
IDO1 P14902 2/20 0.48
HRH3 Q9Y5N1 1/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
MAOB P27338 1/20 0.45
FDPS P14324 1/20 0.43
NPC1 O15118 1/20 0.42
ATM Q13315 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
DAO P14920 2/20 0.41
ALOX5 P09917 1/20 0.41
ACHE P22303 2/20 0.41
SLC5A2 P31639 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7990214 0.94 TAAR1 (0.53) TAAR1ALDH1A1CYP2D6IDO1HRH3
SCHEMBL7998439 0.93 TAAR1 (0.52) TAAR1ALDH1A1CYP2D6IDO1HRH3
SCHEMBL8000063 0.93 TAAR1 (0.52) TAAR1ALDH1A1CYP2D6IDO1HRH3
SCHEMBL7989614 0.93 TAAR1 (0.52) TAAR1ALDH1A1CYP2D6IDO1HRH3
SCHEMBL15432887 0.90 TAAR1 (0.49) TAAR1ALDH1A1CYP2D6IDO1HRH3
SCHEMBL10204841 0.88 TAAR1 (0.59) TAAR1ALDH1A1CYP2D6IDO1HRH3
SCHEMBL8099771 0.83 TAAR1 (0.68) TAAR1IDO1HRH3FDPSDAO
SCHEMBL8092500 0.83 TAAR1 (0.68) TAAR1IDO1HRH3FDPSDAO
SCHEMBL16248161 0.81 TAAR1 (0.52) TAAR1ALDH1A1CYP2D6IDO1HRH3
SCHEMBL14972583 0.81 TAAR1 (0.52) TAAR1ALDH1A1CYP2D6IDO1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3274352-A1 HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR Bayer Pharma Aktiengesellschaft (DE) 2018-01-31 EP disclosed
US-9745313-B2 Macrocycles as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-08-29 US disclosed
US-20170145029-A1 CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF Bayer Pharma AG (DE) 2017-05-25 US disclosed
US-9604996-B2 Cyclic thienouracil-carboxamides and use thereof BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-03-28 US disclosed
US-20160362414-A1 MACROCYCLES AS FACTOR XIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2016-12-15 US disclosed
WO-2016150901-A1 HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-09-29 WO disclosed
US-20160244461-A1 CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-08-25 US disclosed
US-8063105-B2 Renin inhibitors MERCK CANADA INC. (CA) 2011-11-22 US disclosed
US-20090281103-A1 Renin Inhibitors MERCK CANADA INC. (CA) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160362414-A1 MACROCYCLES AS FACTOR XIA INHIBITORS TFPI, TFPI2, F11 TAAR1 4566/4885ALDH1A1 4598/4885CYP2D6 3600/4885
US-20160244461-A1 CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF TYMS, TPMT, PDF TAAR1 1871/4885ALDH1A1 1328/4885CYP2D6 1447/4885
US-20090281103-A1 Renin Inhibitors REN, ACE, AGT TAAR1 3031/4885ALDH1A1 2078/4885CYP2D6 249/4885
US-20170145029-A1 CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF TYMS, TPMT, PDF TAAR1 1871/4885ALDH1A1 1328/4885CYP2D6 1447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.